What's in a Name? That Which We Call Immune Cells by Any Other Name Would All Smell as Sweet
- Author(s)
- Salgado, R; Loi, S;
- Details
- Publication Year 2022-07-01,Volume 28,Issue #13,Page 2728-2729
- Journal Title
- Clinical Cancer Research
- Publication Type
- Commentary
- Abstract
- In the FUTURE-C-Plus phase II trial, patients with advanced previously untreated immune-enriched triple-negative breast cancer achieved an overall objective response rate of 81.3% with the combination of camrelizumab, famitinib, and nab-paclitaxel. This supports that the quantity of immune cells is important for identifying those with response to treatments combined with PD-1-targeting immunotherapy. See related article by Chen et al., p. 2807.
- Keywords
- Albumins/administration & dosage; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols/adverse effects; Humans; Indoles; Paclitaxel/administration & dosage; Pyrroles; *Triple Negative Breast Neoplasms/drug therapy
- Department(s)
- Laboratory Research; Medical Oncology
- PubMed ID
- 35442426
- Publisher's Version
- https://doi.org/10.1158/1078-0432.CCR-22-0783
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2025-04-03 06:48:11
Last Modified: 2025-04-03 06:49:14